gpr35 agonist 1

GPR35 agonist 1 is a highly effective and specific GPR35 CXCR8 agonist (EC50: 5.8 nM).

CID 2745687 是一种对人类 GPR35 具有中等效力、浓度依赖性的拮抗剂，其 pIC50 为 6.70。CID 2745687 无法在体外有效拮抗 Zaprinast 或 Cromolyn disodium 在啮齿动物 GPR35 同源物上的激动作用[1]。然而，CID 2745687 在小鼠体内能够逆转 Lodoxamide 介导的抗纤维化效果[2]。

GPR35 agonist 4 (compound 10) 是一种有效的GPR35激动剂，其效价 pEC50为 5.86。GPR35 agonist 4 在人和大鼠 GPR35 中均显示高效价。精氨酸 3.36 的突变体可消除 GPR35 agonist 4 的激动剂功能。

Bufrolin，作为Cromoglycate（组胺释放抑制剂）的类似物，是一种高效的GPR35激动剂，能够促进β-arrestin-2与人GPR35a或大鼠GPR35之间的相互作用。此外，Bufrolin亦可作为抗过敏性肥大细胞稳定剂，有效抑制内化肽诱导的抗炎反应，并且在内化肽连接药剂的药物递送研究中，被作为抗炎剂使用。

Kynurenic acid, an active metabolite of tryptophan, is synthesized through a kynurenine intermediate by kynurenine aminotransferases (KATs). It acts as an antagonist of both NMDA and AMPA receptors, as well as α7 nicotinic acetylcholine receptors (nAChRs; EC50s = 235, 101, and 7 µM, respectively), and functions as an agonist for the aryl hydrocarbon receptor (AhR) and G protein-coupled receptor 35 (GPR35; EC50s = 1.4 and 39 µM, respectively). In a neonatal rat model of cerebral hypoxic-ischemia, induced by carotid artery ligation, administration of kynurenic acid at 300 mg kg prevents weight loss in the lesioned hemisphere. Additionally, at concentrations of 1 and 5 mg ml, it protects against neurodegeneration in the rhabdomere of the eye in an Htt93QtransgenicDrosophila model of Huntington's disease. Elevated levels of kynurenic acid in the cerebrospinal fluid have been observed in patients with schizophrenia.

GPR35 agonist5（3,5-dinitro-bisphenol A; compound 6）作为一种弱GPR35激动剂，能够将CHO-S细胞阻滞在G1 Go期。